regulator of G protein signaling 12Genealiases: []
Q-omics provides the consensus-scored RGS12 profile across patient tissues and cancer cell-line models. RGS12 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RGS12 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, RGS12 RNA expression shows 19,411 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KICH, and TGCT as cancer lineages where RGS12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RGS12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RGS12 survival associations across molecular data types. RGS12 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RGS12 RNA expression–survival associations across cancer types. High RGS12 expression shows unfavorable associations in MESO, but favorable associations in KIRP, UCS, KIRC, READ and BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RGS12 RNA expression.
This table summarizes RGS12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RGS12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RGS12 shows lower tumor expression in KICH and LUAD and higher tumor expression in KIRC, COAD, LIHC and KIRP. The KICH box plot shows higher RGS12 RNA expression in normal versus tumor tissue (log2 FC = −1.188, t-test p < 0.001).
This table shows molecular features associated with RGS12 in patient tissues and cancer cell lines. In patient samples, RGS12 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RGS12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
